Jedd D. Wolchok
Memorial Sloan Kettering Cancer Center · 1,486 works · 207,563 citations · h-index 175
Top works
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- Cancer immunotherapy using checkpoint blockade
- Immune Checkpoint Blockade in Cancer Therapy
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma